A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC).
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2013
At a glance
- Drugs Firtecan pegol (Primary) ; Cetuximab; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- 16 Sep 2013 Results published in Cancer.
- 30 Jan 2012 Primary endpoint 'Progression-free-survival-duration' has been met.
- 01 Oct 2011 New source identified and integreated (M.D. Anderson Cancer Center).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History